US4682645A
(en)
*
|
1986-03-03 |
1987-07-28 |
Olin Corporation |
Control system for electromagnetic casting of metals
|
US4963681A
(en)
*
|
1987-07-06 |
1990-10-16 |
Norwich Eaton Pharmaceuticals, Inc. |
Process for synthesis of aminomethylene phosphonoalkylphosphinates
|
US5212164A
(en)
*
|
1988-08-29 |
1993-05-18 |
E. R. Squibb & Sons, Inc. |
Phosphorus-containing squalene synthetase inhibitors
|
EP0356866A3
(fr)
*
|
1988-08-29 |
1991-03-27 |
E.R. SQUIBB & SONS, INC. |
Inhibiteurs phosphorés de la synthétase du squalène et procédé
|
CA2007641A1
(fr)
*
|
1989-02-01 |
1990-08-01 |
Donald S. Karanewsky |
Combinaison d'un inhibiteur de squalene synthetase et d'autres types d'agents reducteurs du cholesterol sanguin et methode pour abaisser le taux de cholesterol sanguin en employant une telle combinaison
|
CA2007643A1
(fr)
*
|
1989-02-01 |
1990-08-01 |
Donald S. Karanewsky |
Combinaison d'un inhibiteur de hmg coa et d'un inhibiteur de squalene synthetase et methode pour abaisser le taux de cholesterol sanguin par l'utilisation de cette combinaison
|
CA2016467A1
(fr)
*
|
1989-06-05 |
1990-12-05 |
Martin Eisman |
Methode de traitement de l'atherosclerose des vaisseaux peripheriques a l'aide d'un inhibiteur de l'hmg coa reductase et (ou) d'un inhibiteur de la squalene synthetase
|
CA2018470A1
(fr)
*
|
1989-07-17 |
1991-01-17 |
Scott Adams Biller |
Inhibiteurs de la synthetase de la squalene contenant du soufre, et methode pour ceux-ci
|
IL97251A0
(en)
*
|
1990-03-21 |
1992-05-25 |
Merck & Co Inc |
Antihypercholesterolemic 2,8-dioxabicyclo(3,2,1)octane derivatives,their preparation and pharmaceutical compositions containing them
|
US5096923A
(en)
*
|
1990-03-21 |
1992-03-17 |
Merck & Co., Inc. |
Novel squalene synthetase inhibitors
|
US5132320A
(en)
*
|
1990-03-21 |
1992-07-21 |
Merck & Co., Inc. |
Squalene synthetase inhibitors
|
US5055487A
(en)
*
|
1990-03-21 |
1991-10-08 |
Merck & Co., Inc. |
Novel anti-fungal compounds
|
US6630502B2
(en)
|
1990-05-15 |
2003-10-07 |
E.R. Squibb & Sons, Inc. |
Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
|
US5298497A
(en)
*
|
1990-05-15 |
1994-03-29 |
E. R. Squibb & Sons, Inc. |
Method for preventing onset of hypertension employing a cholesterol lowering drug
|
US5102907A
(en)
*
|
1990-09-13 |
1992-04-07 |
Merck & Co., Inc. |
Novel squalene synthetase inhibitors
|
US5026554A
(en)
*
|
1990-09-13 |
1991-06-25 |
Merck & Co., Inc. |
Method of inhibiting fungal growth using squalene synthetase inhibitors
|
CA2067974A1
(fr)
*
|
1991-05-13 |
1992-11-14 |
Scott A. Biller |
Methode pour abaisser le taux de cholesterol grace a un phosphonomethylphosphinate, inhibiteur de la squalene synthetase
|
US5364948A
(en)
*
|
1991-08-02 |
1994-11-15 |
Merck & Co., Inc. |
Biologically active compounds isolated from aerobic fermentation of Trichoderma viride
|
EP0526936A3
(en)
|
1991-08-02 |
1993-05-05 |
Merck & Co. Inc. |
Cholesterol-lowering agents
|
JPH05239075A
(ja)
*
|
1991-08-27 |
1993-09-17 |
Eisai Co Ltd |
含リンイソプレノイド誘導体
|
US5298655A
(en)
*
|
1991-09-27 |
1994-03-29 |
Merck & Co., Inc. |
Farnesyl pyrophosphate analogs
|
ATE179607T1
(de)
*
|
1991-10-07 |
1999-05-15 |
Tno |
Verwendung von polyisoprenyl pyrophosphate analogen zur hemmung des proteinisoprenylations
|
DE69204007T2
(de)
*
|
1991-10-11 |
1996-03-21 |
Squibb & Sons Inc |
Verwendung von Farnesyl-Protein Transferaseinhibitoren zur Herstellung eines Arzneimittels zur Blockierung von durch Ras-Oncogenen hervorgerufenen neoplastischen Transformationen von Zellen.
|
EP0541037A3
(en)
*
|
1991-11-06 |
1997-02-26 |
Takeda Chemical Industries Ltd |
Squalene synthetase inhibitory composition and use thereof
|
US5200554A
(en)
*
|
1992-01-21 |
1993-04-06 |
Nasman Jan Anders H |
Bisphosphonic acid derivatives and their use
|
US5278153A
(en)
*
|
1992-05-18 |
1994-01-11 |
E. R. Squibb & Sons, Inc. |
Aryl and heteroaryl (phosphinylmethyl)phosphonate squalene synthetase inhibitors and method
|
US5283256A
(en)
*
|
1992-07-22 |
1994-02-01 |
Merck & Co., Inc. |
Cholesterol-lowering agents
|
US5254544A
(en)
*
|
1992-09-25 |
1993-10-19 |
E. R. Squibb & Sons, Inc. |
Hydroxyphosphinyl phosphonate squalene synthetase inhibitors and method
|
US5332728A
(en)
*
|
1992-11-23 |
1994-07-26 |
Bristol-Myers Squibb Company |
Method for treating a fungal infection
|
US5362752A
(en)
*
|
1993-05-17 |
1994-11-08 |
Merck & Co., Inc. |
Chemical compounds
|
US5712261A
(en)
*
|
1993-10-04 |
1998-01-27 |
Magnin; David R. |
Method for preventing or treating hypertriglyceridemia
|
IL115420A0
(en)
|
1994-09-26 |
1995-12-31 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
US5574025A
(en)
*
|
1994-10-26 |
1996-11-12 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferases
|
AU1608397A
(en)
|
1996-02-02 |
1997-08-22 |
Zeneca Limited |
Heterocyclic compounds useful as pharmaceutical agents
|
EP0790235A1
(fr)
|
1996-02-15 |
1997-08-20 |
Sankyo Company Limited |
Dérivés de diaryle-alkanes contenant un groupe alicyclique, leur préparation et leurs applications thérapeutiques et prophylactiques
|
US20020086380A1
(en)
*
|
1996-03-29 |
2002-07-04 |
Francis X. Cunningham Jr |
Genes encoding epsilon lycopene cyclase and method for producing bicyclic carotene
|
CN1228087A
(zh)
*
|
1996-08-14 |
1999-09-08 |
曾尼卡有限公司 |
取代的嘧啶衍生物和它们的药物用途
|
UA56197C2
(uk)
|
1996-11-08 |
2003-05-15 |
Зенека Лімітед |
Гетероциклічні похідні
|
JP2001511799A
(ja)
|
1997-02-13 |
2001-08-14 |
ゼネカ・リミテッド |
オキシド−スクアレンシクラーゼ阻害剤として有用なヘテロ環式化合物
|
EP0966460A1
(fr)
|
1997-02-13 |
1999-12-29 |
Zeneca Limited |
Composes heterocycliques utilises comme inhibiteurs de l'oxydo-squalene cyclase
|
GB9715895D0
(en)
|
1997-07-29 |
1997-10-01 |
Zeneca Ltd |
Heterocyclic compounds
|
CA2331343C
(fr)
|
1998-07-06 |
2014-01-14 |
Dcv, Inc., Doing Business As Bio-Technical Resources |
Production d'isoprenoide dans une levure recombinante
|
US6531303B1
(en)
*
|
1998-07-06 |
2003-03-11 |
Arkion Life Sciences Llc |
Method of producing geranylgeraniol
|
GB9902989D0
(en)
|
1999-02-11 |
1999-03-31 |
Zeneca Ltd |
Heterocyclic derivatives
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
DE10030375A1
(de)
*
|
2000-06-21 |
2002-01-03 |
Bayer Ag |
Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
|
US20040249219A1
(en)
*
|
2000-07-05 |
2004-12-09 |
Saucy Gabriel G. |
Method of making teprenone
|
HUP0600232A2
(en)
|
2001-04-11 |
2006-08-28 |
Bristol Myers Squibb Co |
Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
|
RU2353625C2
(ru)
*
|
2001-10-18 |
2009-04-27 |
Бристол-Маерс Сквибб Компани |
Миметики человеческого глюканоподобного пептида-1 и их применение в лечении диабета и родственных состояний
|
US7238671B2
(en)
*
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
US6806381B2
(en)
*
|
2001-11-02 |
2004-10-19 |
Bristol-Myers Squibb Company |
Process for the preparation of aniline-derived thyroid receptor ligands
|
AU2002348276A1
(en)
*
|
2001-11-16 |
2003-06-10 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
US6831102B2
(en)
*
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
US6747048B2
(en)
|
2002-05-08 |
2004-06-08 |
Bristol-Myers Squibb Company |
Pyridine-based thyroid receptor ligands
|
KR101069781B1
(ko)
*
|
2002-05-14 |
2011-10-05 |
프라샌트 인베스트먼츠, 엘엘씨 |
전송 신호를 생성하는 방법
|
US7057046B2
(en)
*
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
DE60332856D1
(de)
*
|
2002-10-23 |
2010-07-15 |
Bristol Myers Squibb Co |
Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
TW200504021A
(en)
*
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
WO2004066929A2
(fr)
*
|
2003-01-24 |
2004-08-12 |
Bristol-Myers Squibb Company |
Cycloalkyle contenant des ligands anilide pour le recepteur des hormones thyroidiennes
|
WO2004085448A2
(fr)
*
|
2003-03-19 |
2004-10-07 |
Genzyme Corporation |
Inhibiteurs du transport de phosphate comprenant un groupe phosphinyl-phosphonate insature
|
US7557143B2
(en)
*
|
2003-04-18 |
2009-07-07 |
Bristol-Myers Squibb Company |
Thyroid receptor ligands
|
US7459474B2
(en)
*
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US6995183B2
(en)
*
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7371759B2
(en)
*
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
CA2545311C
(fr)
*
|
2003-11-12 |
2012-01-03 |
Phenomix Corporation |
Composes heterocycliques d'acide boronique
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7420059B2
(en)
*
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
ES2399721T5
(es)
|
2004-03-05 |
2016-05-25 |
Univ Pennsylvania |
Métodos para tratar trastornos o enfermedades asociados a la hiperlipidemia e hipercolesterolemia minimizando los efectos adversos
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
US7145040B2
(en)
*
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
TW200611704A
(en)
*
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
JP2008505975A
(ja)
*
|
2004-07-12 |
2008-02-28 |
フェノミックス コーポレーション |
制約されたシアノ化合物
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
US8828684B2
(en)
|
2004-07-27 |
2014-09-09 |
The Regents Of The University Of California |
Genetically modified host cells and use of same for producing isoprenoid compounds
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
US7517991B2
(en)
*
|
2004-10-12 |
2009-04-14 |
Bristol-Myers Squibb Company |
N-sulfonylpiperidine cannabinoid receptor 1 antagonists
|
US7635699B2
(en)
*
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7589088B2
(en)
*
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7368458B2
(en)
*
|
2005-01-12 |
2008-05-06 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7314882B2
(en)
*
|
2005-01-12 |
2008-01-01 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
WO2006076569A2
(fr)
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Heterocycles bicycliques servant de modulateurs aux recepteurs cannabinoides
|
US20060160850A1
(en)
*
|
2005-01-18 |
2006-07-20 |
Chongqing Sun |
Bicyclic heterocycles as cannabinoid receptor modulators
|
ATE421518T1
(de)
*
|
2005-02-10 |
2009-02-15 |
Bristol Myers Squibb Co |
Dihydrochinazolinone als 5ht-modulatoren
|
US20060235028A1
(en)
|
2005-04-14 |
2006-10-19 |
Li James J |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
AR053495A1
(es)
*
|
2005-05-26 |
2007-05-09 |
Bristol Myers Squibb Co |
Moduladores del peptido 1 similar al glucagon humano y su uso en el tratamiento de la diabetes y condiciones relacionadas
|
US20060287342A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Mikkilineni Amarendra B |
Triazolopyrimidine heterocycles as cannabinoid receptor modulators
|
TW200726765A
(en)
*
|
2005-06-17 |
2007-07-16 |
Bristol Myers Squibb Co |
Triazolopyridine cannabinoid receptor 1 antagonists
|
US7629342B2
(en)
*
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
US7317012B2
(en)
*
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
US7452892B2
(en)
*
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
US7632837B2
(en)
*
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
MY141191A
(en)
*
|
2005-07-26 |
2010-03-31 |
Colgate Palmolive Co |
Toothbrush
|
CN101268075A
(zh)
*
|
2005-07-28 |
2008-09-17 |
百时美施贵宝公司 |
作为5-羟色胺受体激动剂和拮抗剂的取代的四氢-1h吡啶并[4,3,b]吲哚
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
JP2009511639A
(ja)
*
|
2005-10-18 |
2009-03-19 |
エージェリオン ファーマシューティカルズ |
血清コレステロールおよび/または血清トリグリセリドを低下させるための組成物
|
AR056155A1
(es)
*
|
2005-10-26 |
2007-09-19 |
Bristol Myers Squibb Co |
Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
|
WO2007053819A2
(fr)
|
2005-10-31 |
2007-05-10 |
Bristol-Myers Squibb Company |
Inhibiteurs à base d'amide et de bêta-amino de pyrrolidinyle de la dipeptidyl peptidase iv et procédés
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
WO2007082264A2
(fr)
*
|
2006-01-11 |
2007-07-19 |
Bristol-Myers Squibb Company |
Modulateurs de peptides 1 de type glucagon humain et leur utilisation pour traiter le diabète et des états associés
|
US7553836B2
(en)
*
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
US20070238770A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
MX2008013304A
(es)
|
2006-04-20 |
2008-10-27 |
Amgen Inc |
Compuestos de peptido 1 tipo glucagon.
|
US7803778B2
(en)
|
2006-05-23 |
2010-09-28 |
Theracos, Inc. |
Glucose transport inhibitors and methods of use
|
WO2007139589A1
(fr)
*
|
2006-05-26 |
2007-12-06 |
Bristol-Myers Squibb Company |
Modulateurs des récepteurs de glp-1 à libération prolongée
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US20080044326A1
(en)
*
|
2006-07-04 |
2008-02-21 |
Esencia Co., Ltd. |
Sterilizer for baby products
|
WO2008057862A2
(fr)
|
2006-11-01 |
2008-05-15 |
Bristol-Myers Squibb Company |
Modulateurs de récepteur de glucocorticoïde, d'activité ap-1 et/ou nf-κb, et leur utilisation
|
JP2010513534A
(ja)
*
|
2006-12-21 |
2010-04-30 |
エージェリオン ファーマシューティカルズ, インコーポレイテッド |
Mtpインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
|
PE20090185A1
(es)
|
2007-03-22 |
2009-02-28 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
JP2010528023A
(ja)
*
|
2007-05-18 |
2010-08-19 |
ブリストル−マイヤーズ スクイブ カンパニー |
Sglt2阻害剤の結晶構造およびその製造方法
|
US20090011994A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
WO2009018065A2
(fr)
*
|
2007-07-27 |
2009-02-05 |
Bristol-Myers Squibb Company |
Nouveaux activateurs de glucokinase et procédés pour les utiliser
|
AU2008288770B2
(en)
|
2007-08-23 |
2014-06-12 |
Theracosbio, Llc |
Benzylbenzene derivatives and methods of use
|
PE20091928A1
(es)
*
|
2008-05-29 |
2009-12-31 |
Bristol Myers Squibb Co |
Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
|
BRPI0916769A2
(pt)
|
2008-07-15 |
2017-09-26 |
Theracos Inc |
derivados de benzilbenzeno deuterados e métodos de uso
|
AU2010229653A1
(en)
|
2009-03-27 |
2011-10-20 |
Astrazeneca Ab |
Methods for preventing major adverse cardiovascular events with DPP-IV inhibitors
|
WO2011060256A2
(fr)
|
2009-11-13 |
2011-05-19 |
Bristol-Myers Squibb Company |
Formulations de comprimé bicouche
|
RU2564901C2
(ru)
|
2009-11-13 |
2015-10-10 |
Бристол-Майерс Сквибб Кампани |
Композиции метформина с уменьшенной массой
|
PL2498759T3
(pl)
|
2009-11-13 |
2019-03-29 |
Astrazeneca Ab |
Formulacje tabletek o natychmiastowym uwalnianiu
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
JP2013523894A
(ja)
|
2010-04-14 |
2013-06-17 |
ブリストル−マイヤーズ スクイブ カンパニー |
新規グルコキナーゼアクチベーターおよびその使用方法
|
WO2011153712A1
(fr)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène
|
RU2016125229A
(ru)
|
2010-07-09 |
2018-12-04 |
БиЭйчВи ФАРМА, ИНК. |
Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина
|
WO2012018950A1
(fr)
|
2010-08-03 |
2012-02-09 |
Beth Israel Deaconess Medical Center |
Procédés et compositions pour le traitement de troubles métaboliques
|
US20130156720A1
(en)
|
2010-08-27 |
2013-06-20 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
US9200025B2
(en)
|
2012-11-20 |
2015-12-01 |
Lexicon Pharmaceuticals, Inc. |
Inhibitors of sodium glucose cotransporter 1
|
WO2015027021A1
(fr)
|
2013-08-22 |
2015-02-26 |
Bristol-Myers Squibb Company |
Dérivés imide et acylurée utilisés comme modulateurs du récepteur de glucocorticoïdes
|
BR112017023158A2
(pt)
|
2015-04-30 |
2018-07-24 |
Harvard College |
anticorpos anti-ap2 e agentes de ligação de antígeno para tratar distúrbios metabólicos
|
EP3823631A1
(fr)
|
2018-07-19 |
2021-05-26 |
Astrazeneca AB |
Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci
|
SG11202102498UA
(en)
|
2018-09-26 |
2021-04-29 |
Lexicon Pharmaceuticals Inc |
Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
|